Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

Comparison of serological assays to titrate Hantaan and Seoul hantavirus-specific antibodies

Authors: Weihong Li, Shouchun Cao, Quanfu Zhang, Jiandong Li, Shuo Zhang, Wei Wu, Jing Qu, Chuan Li, Mifang Liang, Dexin Li

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

Hantaan and Seoul viruses, in the Hantavirus genus, are known to cause hemorrhagic fever with renal syndrome (HFRS). The plaque reduction neutralization test (PRNT), as conventional neutralization test for hantaviruses, is laborious and time-consuming. Alternatives to PRNT for hantaviruses are required.

Methods

In this study, the methods for Hantaan and Seoul viruses serological typing including microneutralization test (MNT), pseudoparticle neutralization test (PPNT) and immunofluorescence assay based on viral glycoproteins (IFA-GP) were developed and compared with PRNT using a panel of 74 sera including 44 convalescent sera of laboratory confirmed HFRS patients and 30 patients sera of non-hantavirus infection. Antibody titres and serotyping obtained with different methods above were analyzed by paired-t, linear correlation, McNemar χ2 and Kappa agreement tests.

Results

Antibody titres obtained with MNT50, PPNT50 and IFA-GP were significantly correlated with that obtained with PRNT50 (p < 0.001). GMT determined by PPNT50 was statistically higher than that determined by PRNT50 (p < 0.001), while GMT determined by MNT50 and IFA-GP were equal with (p > 0.05) and less than (p < 0.001) that obtained with PRNT50 respectively. Serotyping obtained with MNT50 and PRNT50, PPNT50 and PRNT50 were highly consistent (p < 0.001), whereas that obtained with IFA-GP and PRNT50 were moderately consistent (p < 0.001). There were no significant differences for serotyping between PRNT50 and MNT50, as well as PRNT50 and PPNT50 (p > 0.05). IFA-GP was less sensitive than PRNT50 and MNT50 for serotyping of hantaviruses infection (p < 0.05). However, for 79.5% (35/44) samples, serotyping determined by IFA-GP and PRNT50 were consistent.

Conclusions

MNT50 and PPNT50 both can be used as simple and rapid alternatives to PRNT50, and MNT50 is more specific while PPNT50 is more sensitive than other assays for neutralizing antibody determination. So far, this work has been the most comprehensive comparison of alternatives to PRNT.
Literature
1.
Schmaljohn CS, Hasty SE, Dalrymple JM, et al. Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome. Science. 1985;227(4690):1041–4.CrossRefPubMed
2.
3.
Walter CT, Barr JN. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol. 2011;92:2467–84.CrossRefPubMed
4.
Muyangwa M, Martynova EV, Khaiboullina SF, et al. Hantaviral proteins: structure, functions, and role in hantavirus infection. Front Microbiol. 2015;6:1326.CrossRefPubMedPubMedCentral
5.
6.
Arikawa J, Schmaljohn AL, Dalrymple JM, et al. Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J Gen Virol. 1989;70:615–24.CrossRefPubMed
7.
Dantas JR Jr, Okuno Y, Asada H, et al. Characterization of glycoproteins of viruses causing hemorrhagic fever with renal syndrome (HFRS) using monoclonal antibodies. Virology. 1986;151(2):379–84.CrossRefPubMed
8.
Hooper JW, Custer DM, Thompson E, et al. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titre neutralizing antibody response in rhesus monkeys. J Virol. 2001;75:8469–77.CrossRefPubMedPubMedCentral
9.
10.
Hart CA, Bennett M. Hantavirus infections: epidemiology and pathogenesis. Microbes Infect. 1999;1(14):1229–37.CrossRefPubMed
11.
Song G. Epidemiological progresses of hemorrhagic fever with renal syndrome in China. Chin Med J. 1999;112(5):472–7.PubMed
12.
13.
Chu YK, Jennings G, Schmaljohn A, et al. Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients. J Infect Dis. 1995;172(6):1581–4.CrossRefPubMed
14.
Lee PW, Gibbs CJ Jr, Gajdusek DC, et al. Serotypic classification of hantaviruses by indirect immunofluorescent antibody and plaque reduction neutralization tests. J Clin Microbiol. 1985;22(6):940–4.PubMedPubMedCentral
15.
Yu YX, Yao ZH, An Q, et al. Studies on serotypic classification of viruses of hemorrhagic fever with renal syndrome by plaque reduction neutralization test. Bing Du Xue Bao. 1991;7:18–22.
16.
Anderson LJ, Hierholzer JC, Bingham PG, et al. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol. 1985;22(6):1050–2.PubMedPubMedCentral
17.
Kenny MT, Albright KL, Sanderson RP. Microneutralization test for the determination of mumps antibody in vero cells. Appl Microbiol. 1970;20(3):371–3.PubMedPubMedCentral
18.
Mannen K, Mifune K, Reid-Sanden FL, et al. Microneutralization test for rabies virus based on an enzyme immunoassay. J Clin Microbiol. 1987;25(12):2440–2.PubMedPubMedCentral
19.
Vorndam V, Beltran M. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg. 2002;66(2):208–12.CrossRefPubMed
20.
Benne CA, Harmsen M, De Jong JC, et al. Neutralization enzyme immunoassay for influenza Virus. J Clin Microbiol. 1994;32(4):987–90.PubMedPubMedCentral
21.
22.
Hörling J, Lundkvist A, Huggins JW, et al. Antibodies to Puumala virus in humans determined by neutralization test. J Virol Methods. 1992;39(1–2):139–47.CrossRefPubMed
23.
24.
25.
Garcia JM, Lai JC. Production of influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update. Expert Rev Anti-Infect Ther. 2016;9(4):443–55.CrossRef
26.
Garcia JM, Lagarde N, Ma ES, et al. Optimization and evaluation of an influenza a (H5) pseudotyped lentiviral particle-based serological assay. J Clin Virol. 2010;47:29–33.CrossRefPubMed
27.
Hofmann H, Li X, Zhang X, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013;87(8):4384–94.CrossRefPubMedPubMedCentral
28.
Cifuentes-Muñoz N, Darlix JL, Tischler ND. Development of a lentiviral vector system to study the role of the Andes virus glycoproteins. Virus Res. 2010;153(1):29–35.CrossRefPubMed
29.
Qian Z, Haessler M, Lemos JA, et al. Targeting vascular injury using hantavirus-pseudotyped lentiviral vectors. Mol Ther. 2006;13(4):694–704.CrossRefPubMed
30.
Ma M, Kersten DB, Kamrud KI, et al. Murine leukemia virus pseudotypes of La Crosse and Hantaan Bunyaviruses: a system for analysis of cell tropism. Virus Res. 1999;64(1):23–32.CrossRefPubMed
31.
Ogino M, Ebihara H, Lee BH, et al. Use of vesicular stomatitis virus pseudotypes bearing hantaan or seoul virus envelope proteins in a rapid and safe neutralization test. Clin Diagn Lab Immunol. 2003;10(1):154–60.PubMedPubMedCentral
32.
Ray N, Whidby J, Stewart S, et al. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods. 2010;163(2):416–23.CrossRefPubMed
33.
Higa MM, Petersen J, Hooper J, et al. Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology. 2012;423(2):134–42.CrossRefPubMed
34.
Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76(24):13001–14.CrossRefPubMedPubMedCentral
35.
Liang MF, Song G, Hang CS, et al. Preliminary study on structure protein of epidemic hemorrhagic fever virus using monoclonal antibodies. Bing Du Xue Bao. 1989;5(3):217–23.
36.
Koch J, Liang M, Queitsch I, et al. Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology. 2003;308:64–73.CrossRefPubMed
37.
Zhang QF, Li JD, Li WH, et al. Development and application of a two-step MacELISA for the early diagnosis of hemorrhagic fever with renal syndrome. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2008;22(1):6–8.PubMed
38.
Zöller L, Yang S, Gött P, et al. Use of recombinant nucleocapsid proteins of the Hantaan and nephropathia epidemica serotypes of hantaviruses as immunodiagnostic antigens. J Med Virol. 1993;39(3):200–7.CrossRefPubMed
39.
Pang Z, Li A, Li J, et al. Comprehensive multiplex one-step real-time TaqMan qRT-PCR assays for detection and quantification of hemorrhagic fever viruses. PLoS One. 2014;9(4):e95635.CrossRefPubMedPubMedCentral
40.
Chu YK, Rossi C, Leduc JW, et al. Serological relationships among viruses in the hantavirus genus, family Bunyaviridae. Virology. 1994;198(1):196–204.CrossRefPubMed
41.
Connor RI, Chen BK, Choe S, et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995;206(2):935–44.CrossRefPubMed
42.
Vaheri A, Vapalahti O, Plyusnin A. How to diagnose hantavirus infections and detect them in rodents and insectivores. Rev Med Virol. 2008;18(4):277–88.CrossRefPubMed
43.
Mattar S, Guzmán C, Figueiredo LT. Diagnosis of hantavirus infection in humans. Expert Rev Anti-Infect Ther. 2015;13(8):939–46.CrossRefPubMed
44.
Song G, Hang CS, Liao HX, et al. Antigenic difference between viral strains causing classical and mild types of epidemic hemorrhagic fever with renal syndrome in China. J Infect Dis. 1984;150(6):889–94.CrossRefPubMed
Metadata
Title
Comparison of serological assays to titrate Hantaan and Seoul hantavirus-specific antibodies
Authors
Weihong Li
Shouchun Cao
Quanfu Zhang
Jiandong Li
Shuo Zhang
Wei Wu
Jing Qu
Chuan Li
Mifang Liang
Dexin Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-017-0799-0

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue

Short Report

Comparative epidemiology of porcine circovirus type 3 in pigs with different clinical presentations

Research

Fucoidan from Fucus vesiculosus suppresses hepatitis B virus replication by enhancing extracellular signal-regulated Kinase activation

Research

Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants

Research

Co-infection of two reoviruses increases both viruses accumulation in rice by up-regulating of viroplasm components and movement proteins bilaterally and RNA silencing suppressor unilaterally

Research

Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro

Research

HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits